All subjects were recruited at National Cheng Kung University Hospital. Eligible subjects were over 18 years of age, with a confirmed advanced solid tumor that failed prior systemic therapy, measurable disease, archival tumor tissue, ECOG performance status of 0 or 1, adequate hematologic, hepatic, and renal function and an expected survival of at least 3 months. No anti-cancer therapy could be received in the 2 weeks prior to study entry. Additionally, patients with uncontrolled intercurrent illness, expected noncompliance, history of another primary cancer unless unlikely to affect outcome, prior ADI-PEG 20 therapy, prior immunotherapy, and known allergy to ADI-PEG 20 were ineligible.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.